Promising molecular targets in ovarian cancer
S Blagden, H Gabra - Current opinion in oncology, 2009 - journals.lww.com
Using targeted agents in ovarian cancer, we are discovering not only how these novel
therapies work but are also unveiling the complex 'wiring'of the disease itself, and the …
therapies work but are also unveiling the complex 'wiring'of the disease itself, and the …
The role of targeted therapy in ovarian cancer
S Banerjee, S Kaye - European journal of cancer, 2011 - Elsevier
Ovarian cancer is the second most common gynaecological malignancy and the leading
cause of death from gynaecological cancer. Although in some cases treatment is initially …
cause of death from gynaecological cancer. Although in some cases treatment is initially …
First-line treatment of ovarian cancer: questions and controversies to address
JA Ledermann - Therapeutic advances in medical oncology, 2018 - journals.sagepub.com
There is little doubt that the survival of women with advanced ovarian cancer has improved
over the last two decades. 1 Platinum and paclitaxel are the two key drugs that have now …
over the last two decades. 1 Platinum and paclitaxel are the two key drugs that have now …
Top advances of the year: Ovarian cancer
MA Lumish, EC Kohn, WP Tew - Cancer, 2024 - Wiley Online Library
Although cure rates remain low and effective screening strategies are elusive, the recent
advances in systemic therapies over the past year highlighted in this review have prolonged …
advances in systemic therapies over the past year highlighted in this review have prolonged …
Angiogenesis as a target for the treatment of ovarian cancer
D Shaw, A Clamp, GC Jayson - Current opinion in oncology, 2013 - journals.lww.com
Both the first-line trials stopped maintenance bevacizumab after 12 and 15 months,
respectively; yet, current data suggest that maintenance therapy should continue at least …
respectively; yet, current data suggest that maintenance therapy should continue at least …
New ways to successfully target tumor vasculature in ovarian cancer
X Yang, F Shen, W Hu, RL Coleman… - Current Opinion in …, 2015 - journals.lww.com
When to start and end antiangiogenesis therapy and the choice of optimal treatment
combinations remain controversial. Further evaluation of personalized novel angiogenesis …
combinations remain controversial. Further evaluation of personalized novel angiogenesis …
[PDF][PDF] Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens
The 3rd International Ovarian Cancer Consensus Conference (OCCC), held 3–5 September
2004, in Baden-Baden, Germany, addressed 12 questions critical to the future directions of …
2004, in Baden-Baden, Germany, addressed 12 questions critical to the future directions of …
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop
RC Bast, JT Thigpen, SG Arbuck, K Basen-Engquist… - Gynecologic …, 2007 - Elsevier
OBJECTIVE: The unique characteristics of cancer, particularly issues involving the use of
surrogate endpoints in clinical trials, present special challenges in the development of …
surrogate endpoints in clinical trials, present special challenges in the development of …
Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition
L Martin, R Schilder - Journal of clinical oncology, 2007 - ascopubs.org
Despite an aggressive approach of surgical cytoreduction and adjuvant combination
chemotherapy, ovarian cancer mortality remains a significant problem. We are entering a …
chemotherapy, ovarian cancer mortality remains a significant problem. We are entering a …
The prognostic significance of anti-angiogenesis therapy in ovarian cancer: a meta-analysis
J Li, S Li, R Chen, H Yu, X Lu - Journal of ovarian research, 2015 - Springer
Objective The prognostic value of anti-angiogenesis therapy in ovarian cancer patients is
currently under debate. In this study, we assessed the effects of anti-angiogenesis therapy …
currently under debate. In this study, we assessed the effects of anti-angiogenesis therapy …